PMID- 38324802
OWN - NLM
STAT- MEDLINE
DCOM- 20240209
LR  - 20240210
IS  - 1678-2674 (Electronic)
IS  - 0102-8650 (Print)
IS  - 0102-8650 (Linking)
VI  - 39
DP  - 2024
TI  - Bone protective effect of sinomenine against monosodium iodoacetate induced knee 
      and hip injury in rat model: an inflammatory pathway.
PG  - e390924
LID - S0102-86502024000100203 [pii]
LID - 10.1590/acb390924 [doi]
LID - e390924
AB  - PURPOSE: Osteoarthritis (OA) is a degenerative joint disease which is categorized 
      via destruction of joint cartilage and it also affects the various joints, 
      especially knees and hips. Sinomenine active phytoconstituents isolated from the 
      stem of Sinomenium acutum and already proof anti-inflammatory effect against the 
      arthritis model of rodent. In this experimental protocol, we scrutinized the 
      anti-osteoarthritis effect of sinomenine against monosodium iodoacetate (MIA) 
      induced OA in rats. METHODS: MIA (3 mg/50 muL) was used for inducing the OA in the 
      rats, and rats received the oral administration of sinomenine (2.5, 5 and 7.5 
      mg/kg body weight) up to the end of the experimental study (four weeks). The body 
      and organs weight were estimated. Aggrecan, C-terminal cross-linked telopeptide 
      of type II collagen (CTX-II), glycosaminoglycans (GCGs), monocyte chemoattractant 
      protein-1 (MCP-1), Interferon gamma (IFN-gamma), antioxidant, inflammatory cytokines, 
      inflammatory mediators and matrix metalloproteinases (MMP) were analyzed. 
      RESULTS: Sinomenine significantly (P < 0.001) boosted the body weight and reduced 
      the heart weight, but the weight of spleen and kidney remain unchanged. 
      Sinomenine significantly (P < 0.001) reduced the level of nitric oxide, MCP-1 and 
      improved the level of aggrecan, IFN-gamma and GCGs. Sinomenine remarkably upregulated 
      the level of glutathione, superoxide dismutase and suppressed the level of 
      malonaldehyde. It effectually modulated the level of inflammatory cytokines and 
      inflammatory mediators and significantly (P < 0.001) reduced the level of MMPs, 
      like MMP-1, 2, 3, 9 and 13. CONCLUSIONS: Sinomenine is a beneficial active agent 
      for the treatment of OA disease.
FAU - Lei, Yi-Hao
AU  - Lei YH
AUID- ORCID: 0009-0000-9106-2941
AD  - Affiliated Hospital of Yunnan University, Bone and Traumatic Surgery, Kunming, 
      China.
FAU - Hu, Xing-Xi
AU  - Hu XX
AUID- ORCID: 0009-0004-6963-9117
AD  - Affiliated Hospital of Yunnan University, Bone and Traumatic Surgery, Kunming, 
      China.
FAU - Wen, Hong-Jie
AU  - Wen HJ
AUID- ORCID: 0009-0005-7092-6487
AD  - Affiliated Hospital of Yunnan University, Bone and Traumatic Surgery, Kunming, 
      China.
FAU - Deng, Yong-Cheng
AU  - Deng YC
AUID- ORCID: 0009-0008-0288-6307
AD  - Affiliated Hospital of Yunnan University, Bone and Traumatic Surgery, Kunming, 
      China.
FAU - Jiang, Jun-Liang
AU  - Jiang JL
AUID- ORCID: 0009-0003-0797-8992
AD  - Affiliated Hospital of Yunnan University, Bone and Traumatic Surgery, Kunming, 
      China.
FAU - Zhao, Qing-Gang
AU  - Zhao QG
AUID- ORCID: 0000-0002-3102-6372
AD  - Affiliated Hospital of Yunnan University, Bone and Traumatic Surgery, Kunming, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20240205
PL  - Brazil
TA  - Acta Cir Bras
JT  - Acta cirurgica brasileira
JID - 9103983
RN  - WF5188V710 (Iodoacetic Acid)
RN  - 63LT81K70N (sinomenine)
RN  - 0 (Aggrecans)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
RN  - 0 (Cytokines)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Morphinans)
SB  - IM
MH  - Rats
MH  - Animals
MH  - Iodoacetic Acid/metabolism/pharmacology
MH  - *Osteoarthritis/metabolism
MH  - Aggrecans/metabolism/pharmacology
MH  - Disease Models, Animal
MH  - *Cartilage, Articular/metabolism
MH  - Matrix Metalloproteinases/metabolism
MH  - Cytokines/metabolism
MH  - Inflammation Mediators/metabolism
MH  - Body Weight
MH  - *Morphinans
PMC - PMC10852535
COIS- Conflict of interest: Nothing to declare.
EDAT- 2024/02/07 18:42
MHDA- 2024/02/09 06:43
PMCR- 2024/02/05
CRDT- 2024/02/07 17:12
PHST- 2023/07/22 00:00 [received]
PHST- 2023/09/11 00:00 [accepted]
PHST- 2024/02/09 06:43 [medline]
PHST- 2024/02/07 18:42 [pubmed]
PHST- 2024/02/07 17:12 [entrez]
PHST- 2024/02/05 00:00 [pmc-release]
AID - S0102-86502024000100203 [pii]
AID - 10.1590/acb390924 [doi]
PST - epublish
SO  - Acta Cir Bras. 2024 Feb 5;39:e390924. doi: 10.1590/acb390924. eCollection 2024.